BEACON-HCC:肝细胞癌治疗分配的北美共识
BEACON-HCC 是北美 20 位多学科专家通过改良德尔菲法制定的肝细胞癌治疗分配共识框架,纳入肝内肿瘤负荷程度、血管侵犯及不良预后标志物等特征,并整合外照射放疗、经动脉放射栓塞及系统-局部联合治疗等新兴模式。在 29 例真实病例试点中,专家治疗决策与 BEACON-HCC 推荐的一致率为 96.6%,与 BCLC 推荐的一致率为 72.4%。
要点
- BEACON-HCC 为北美多学科专家共识框架,用于肝细胞癌治疗分配。
- 框架纳入肿瘤负荷、血管侵犯及不良预后标志物等细化特征。
- 试点中专家决策与 BEACON-HCC 一致率 96.6%,高于 BCLC 的 72.4%。
核心结论
- BEACON-HCC 是纳入北美肝细胞癌患者扩展治疗选择的共识治疗分配框架。
- 专家治疗决策与 BEACON-HCC 系统显示高度一致。
研究设计与样本
- 采用改良德尔菲流程,由 20 位北美肝病、肿瘤内科、外科、放射及放射肿瘤学多学科专家制定共识框架。
- 通过迭代讨论和投票,基于当前证据与专家意见形成 BEACON-HCC 系统。
- 试点研究使用 29 例真实世界患者病例,评估外部专家推荐与 BEACON-HCC 及 BCLC 2025 治疗推荐的一致性。
主要发现
- BEACON-HCC 框架纳入肝内肿瘤负荷程度、血管侵犯程度及不良肿瘤预后标志物等细化临床特征。
- 框架整合外照射放疗、经动脉放射栓塞及系统-局部联合治疗等新兴模式。
- 试点中专家治疗决策与 BEACON-HCC 推荐的一致率为 96.6%。
- 试点中专家治疗决策与 BCLC 推荐的一致率为 72.4%。
临床怎么用
- BEACON-HCC 可用于北美肝细胞癌患者的治疗分配决策参考。
- 该框架将治疗分配与肿瘤生物学及治疗潜力对齐,并纳入新兴治疗模式。
- 计划通过 HCC-Live Consortium 使用实证临床数据进一步验证。
局限性
- 试点研究仅基于 29 例真实世界患者病例。
- 尚需使用实证临床数据进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hepatocellular carcinoma (HCC) remains a major cause of cancer-related mortality. Optimal treatment decisions are challenging, and existing treatment allocation frameworks may not fully reflect the evolving therapeutic landscape or contemporary clinical practices in North America. Using a modified Delphi process, a multidisciplinary panel of 20 North American experts in hepatology, medical oncology, surgery, radiology, and radiation oncology developed a consensus-based treatment framework for HCC, termed the BEACON-HCC system. The framework was informed by current evidence and expert opinion through iterative discussion and voting. In a pilot study using 29 real-world patient cases, we assessed concordance between external expert recommendations and BEACON-HCC recommendations and Barcelona Clinic Liver Cancer (BCLC) 2025 treatment recommendations. The BEACON-HCC treatment allocation framework diverges from prior frameworks by incorporating nuanced clinical features such as the degree of intrahepatic tumor burden and vascular invasion, and adverse tumor prognostic markers, to align treatment allocation with tumor biology and therapeutic potential. Key innovations include the incorporation of emerging modalities such as external beam radiation therapy (EBRT), transarterial radioembolization (TARE), and systemic-locoregional combination therapies. In the pilot exercise, expert treatment decisions showed 96.6% concordance with BEACON-HCC recommendations and 72.4% concordance with BCLC recommendations. In conclusion, BEACON-HCC is a consensus-based framework for treatment allocation that incorporates the expanding range of therapeutic options available to patients in the North American HCC population. Expert treatment decisions showed a high concordance with the BEACON-HCC system; further validation using empiric clinical data is planned through the HCC-Live Consortium.
引用
- Singal AG, Agopian VG, Dawson LA, et al. BEACON-HCC: Best evidence and North American consensus on treatment allocation for hepatocellular carcinoma. Hepatology. 2026. PMID: 42565685. doi:10.1097/HEP.0000000000001834
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。